Vertex Pharmaceuticals (VRTX) Gains from Investment Securities (2015 - 2024)
Vertex Pharmaceuticals (VRTX) posted quarterly Gains from Investment Securities of -$1.2 million for Q4 2024, up 97.61% year-over-year from -$607243.5 in Q1 2024, and down 500.0% quarter-over-quarter from $300000.0 in Q3 2024.
Vertex Pharmaceuticals (VRTX) Gains from Investment Securities (2015 - 2024) Analysis & Trends
Vertex Pharmaceuticals' Gains from Investment Securities history runs 9 years deep, the most recent figure standing at -$1.2 million for Q4 2024.
- In Q4 2024, Gains from Investment Securities rose 97.61% year-over-year to -$1.2 million; the TTM figure through Dec 2024 stood at -$500000.0 (up 99.03% YoY), while the FY2024 annual figure was -$500000.0, up 99.03% from the prior year.
- Gains from Investment Securities for Q4 2024 stood at -$1.2 million, down from $300000.0 in the prior quarter.
- The five-year high for Gains from Investment Securities was $9.2 million in Q2 2020, with the low at -$50.3 million in Q4 2023.
- The 5-year median for Gains from Investment Securities is $100000.0 (2024), against an average of -$5.0 million.
- Peak annual rise in Gains from Investment Securities reached 190.0% in 2022, while the deepest fall reached 3175.0% in 2022.
- Vertex Pharmaceuticals' Gains from Investment Securities stood at $500000.0 in 2020, then tumbled by 500.0% to -$2.0 million in 2021, then surged by 190.0% to $1.8 million in 2022, then tumbled by 2894.44% to -$50.3 million in 2023, then jumped by 97.61% to -$1.2 million in 2024.
- Business Quant data shows VRTX's Gains from Investment Securities at -$1.2 million in Q4 2024, $300000.0 in Q3 2024, and $500000.0 in Q2 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | -1.20 Mn |
| Dec 31, 2024 | -1.20 Mn |
| Sep 30, 2024 | 300,000.00 |
| Sep 30, 2024 | 300,000.00 |
| Jun 30, 2024 | 500,000.00 |
| Jun 30, 2024 | 500,000.00 |
| Mar 31, 2024 | -100,000.00 |
| Mar 31, 2024 | -100,000.00 |
| Dec 31, 2023 | -50.30 Mn |
| Dec 31, 2023 | -50.30 Mn |
| Sep 30, 2023 | 1.20 Mn |
| Sep 30, 2023 | 1.20 Mn |
| Jun 30, 2023 | -600,000.00 |
| Jun 30, 2023 | -600,000.00 |
| Mar 31, 2023 | -1.90 Mn |
| Mar 31, 2023 | -1.90 Mn |
| Dec 31, 2022 | 1.80 Mn |
| Dec 31, 2022 | 1.80 Mn |
| Sep 30, 2022 | -2.60 Mn |
| Sep 30, 2022 | -2.60 Mn |